title: The long-term risk of stroke in patients with acute myocardial infarction complicated with new-onset atrial fibrillation.
abstract: BACKGROUND
  The long-term risk of stroke after acute myocardial infarction (AMI) complicated with new-onset atrial fibrillation (AF) remains unclear. The aim of this study was to determine the long-term risk of AF and stroke in patients with AMI complicated with new-onset AF.
  
  
  METHODS
  Patients with AMI complicated with new-onset AF (n = 260) and those without new-onset AF (n = 292) were followed for a mean of 7 years. All patients had sinus rhythm at hospital discharge.
  
  
  RESULTS
  During the follow-up, AMI patients with new-onset AF had more frequent AF than those without new-onset AF (10.4% vs 2.7%, respectively; P < 0.0001). New-onset AF during AMI was a significant predictor of subsequent AF occurrence (the time elapsing between 2 consecutive R waves [RR] = 3.15, P = 0.004); but AF recurrence in follow-up (RR = 5.08, P = 0.001) and non-anticoagulation at discharge (RR = 0.29, P = 0.008) were independent predictors of stroke (Cox regression analysis). A period of 3.5 hours of AF within the first 48 hours of AMI was the high sensitivity cut-off level for the prediction of low long-term risk of stroke obtained by receiver operating characteristic analysis. Among patients who did not receive anticoagulants at discharge, the patients with short AF did not experience stroke and AF recurrence during follow-up, while those in the other group developed it (10.8%, P = 0.038 and 13.5%, P = 0.019, respectively).
  
  
  CONCLUSIONS
  New-onset AF during AMI identifies the patients at long-term risk for stroke who may potentially benefit from anticoagulant therapy. Atrial fibrillation recurrence in follow-up was independently related to the development of stroke. However, for low-risk patients with AF (those with short AF occurring early in AMI) long-term anticoagulants might not be required.
authors.affiliation: Emergency Center, Clinical Center of Serbia, University Institute of Cardiovascular Diseases, Belgrade, Serbia. masanin@Eunet.rs
authors.forename: Milika R
authors.initials: MR
authors.lastname: Asanin
authors.forename: Asanin R
authors.initials: AR
authors.lastname: Milika
authors.forename: Zorana M
authors.initials: ZM
authors.lastname: Vasiljevic
authors.forename: Vasiljevic M
authors.initials: VM
authors.lastname: Zorana
authors.forename: Mihailo D
authors.initials: MD
authors.lastname: Matic
authors.forename: Matic D
authors.initials: MD
authors.lastname: Mihailo
authors.forename: Igor B
authors.initials: IB
authors.lastname: Mrdovic
authors.forename: Mrdovic B
authors.initials: MB
authors.lastname: Igor
authors.forename: Jovan P
authors.initials: JP
authors.lastname: Perunicic
authors.forename: Perunicic P
authors.initials: PP
authors.lastname: Jovan
authors.forename: Danica P
authors.initials: DP
authors.lastname: Matic
authors.forename: Matic P
authors.initials: MP
authors.lastname: Danica
authors.forename: Bosiljka D
authors.initials: BD
authors.lastname: Vujisic-Tesic
authors.forename: Vujisic-Tesic D
authors.initials: VT
authors.lastname: Bosiljka
authors.forename: Sanja D
authors.initials: SD
authors.lastname: Stankovic
authors.forename: Stankovic Dj
authors.initials: SDj
authors.lastname: Sanja
authors.forename: Dragan M
authors.initials: DM
authors.lastname: Matic
authors.forename: Matic M
authors.initials: MM
authors.lastname: Dragan
authors.forename: Miodrag C
authors.initials: MC
authors.lastname: Ostojic
authors.forename: Ostojic C
authors.initials: OC
authors.lastname: Miodrag
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000209:etiology*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications* / Q000188:drug therapy; D018579:Patient Selection; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012372:ROC Curve; D012008:Recurrence; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000209:etiology* / Q000517:prevention & control; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants
references.citation: Stroke. 1993 Oct;24(10):1490-5
references.pmid: 8378952
references.citation: Heart. 2002 Oct;88(4):357-62
references.pmid: 12231591
references.citation: Heart. 2001 Nov;86(5):527-32
references.pmid: 11602545
references.citation: Eur J Heart Fail. 2005 Jun;7(4):671-6
references.pmid: 15921810
references.citation: Chest. 2007 Jul;132(1):44-9
references.pmid: 17400657
references.citation: Neurology. 2000 Jan 25;54(2):288-94
references.pmid: 10668685
references.citation: Jpn Circ J. 1992 Jan;56(1):1-11
references.pmid: 1538570
references.citation: J Am Coll Cardiol. 1997 Aug;30(2):406-13
references.pmid: 9247512
references.citation: Am Heart J. 2000 Dec;140(6):878-85
references.pmid: 11099991
references.citation: N Engl J Med. 1997 Jan 23;336(4):251-7
references.pmid: 8995087
references.citation: Eur Heart J. 1999 May;20(10):748-54
references.pmid: 10329066
references.citation: Circulation. 2000 Mar 7;101(9):969-74
references.pmid: 10704162